
Opinion|Videos|February 24, 2025
Current and Emerging Treatment Landscape of mHSPC
Jack Andrews MD; Eugene Cone, MD; and Arash Rezazadeh, MD, discuss how metastatic hormone-sensitive prostate cancer presents clinically, explore current treatment standards including combination therapies, evaluate emerging data from the ARANOTE trial on darolutamide efficacy, consider quality of life factors in treatment selection, and examine how novel therapeutic approaches may reshape future care pathways.
Advertisement
Timecodes
1:54 mHSPC and Imaging
4:57 Current SOC in mHSPC
10:15 Choosing Therapy in mHSPC
18:51 ARANOTE Trial in mHSPC
21:15 Experience With ARI
27:08 Emerging mHSPC Treatments
32:51 ARANOTE Subgroup Analysis
35:31 Future Outlook for mHSPC
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Cretostimogene Grenadenorepvec: Mechanism and Rationale
5










